Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> ( <scp>ATTR‐ACT</scp> ) and long‐term extension study
Thibaud Damy(Amyloidosis Foundation), Ronald Witteles(Alnylam Pharmaceuticals (United States)), Balarama Gundapaneni(Pfizer (United States)), Marla B. Sultan(Pfizer (United States)), Mazen Hanna(Cleveland Clinic), Terrell A. Patterson(Pfizer (United States)), Pablo García‐Pavía(Universidad Francisco de Vitoria), Daniel P. Judge(Medical University of South Carolina), Jeffrey H. Schwartz(National Museum of American History), Giampaolo Merlini(University of Pavia), Steve Riley(Pfizer (United States))
Cited by 207
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k